Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mefenamic acid is a nonsteroidal anti-inflammatory drug (NSAID) of the anthranilic acid derivative (fenamate) class. It is used for the short-term treatment (up to 7 days) of mild to moderate pain, including primary dysmenorrhea (menstrual pain), and other types of acute pain such as musculoskeletal pain, dental pain, and postoperative pain. Mefenamic acid works primarily by inhibiting cyclooxygenase enzymes COX-1 and COX-2, which are involved in prostaglandin synthesis; this leads to reduced inflammation, analgesia, and antipyresis[1][3][5][6]. The drug was originally developed by Parke-Davis in the 1960s. It should be taken with food due to gastrointestinal side effects common with NSAIDs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mefenamic acid.